Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
KIT NORTON

Tenet Healthcare Earnings Surge 126% As Hospital Operator Now Expects Record Annual EPS

Hospital operator Tenet Healthcare reported better-than-expected first-quarter earnings and revenue early Tuesday and increased its full-year outlook as hospital use trends improve. THC shares jumped Tuesday.

Tenet Healthcare announced Q1 EPS came in at $3.22, up 126% compared to first quarter 2023, while revenue grew 7% to $5.37 billion. Analysts predicted earnings of $1.45 per share and sales totaling $5.15 billion. Tenet's Q1 results also blew past its own Q1 EPS expectations of $1.24-$.150 and its revenue range of $5 billion-$5.2 billion.

The company's hospital segment saw operating revenues increase more than 6% vs. Q1 2023 due primarily to increased admissions and improved pricing. Tenet also saw same-hospital net patient service revenue per adjusted admission grow nearly 9%. This comes as patients appear to be starting to go the hospital for often in recent months, a positive for hospitals and health providers and a negative for insurers.

Tenet also raised its full-year view Tuesday and now forecasts revenue of $20 billion-$20.40 billion in 2024 with earnings between $8.37-$9.41 per share. The health provider previously expected revenue of $19.9 billion-$20.30 billion and EPS between $5.76-$6.90.

Tenet Healthcare stock surged 7.7% to 106.80 during market action Tuesday, setting up a possible jump to record highs after the stock retook support at its 50-day moving average. On Monday, THC advanced 3.1% to 99.15. Shares were down around 5.7% in April as of Monday's close.

Tenet Healthcare stock has a 94 Composite Rating out of a best-possible 99. Shares also have a 92 Relative Strength Rating and a 74 EPS Rating.

Please follow Kit Norton on X, formerly known as Twitter, @KitNorton for more coverage.

YOU MAY ALSO LIKE:

Is Tesla Stock A Buy Or A Sell?

Get Full Access To IBD Stock Lists And Ratings

Learning How To Pick Great Stocks? Read Investor's Corner

Is Rivian A Buy Right Now After It Launched Its New Product Line?

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.